CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia

SHARE